|
1
|
Nagai S, Washiyama K, Kurimoto M, Takaku
A, Endo S and Kumanishi T: Aberrant nuclear factor-kappaB activity
and its participation in the growth of human malignant astrocytoma.
J Neurosurg. 96:909–917. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hayashi S, Yamamoto M, Ueno Y, Ikeda K,
Ohshima K, Soma G and Fukushima T: Expression of nuclear
factor-kappa B, tumor necrosis factor receptor type 1 and c-Myc in
human astrocytomas. Neurol Med Chir (Tokyo). 41:187–195. 2001.
View Article : Google Scholar
|
|
3
|
Bredel M, Bredel C, Juric D, Duran GE, Yu
RX, Harsh GR, Vogel H, Recht LD, Scheck AC and Sikic BI: Tumor
necrosis factor-α-induced protein 3 as a putative regulator of
nuclear factor-κB-mediated resistance to O6-alkylating
agents in human glioblastomas. J Clin Oncol. 24:274–287. 2006.
View Article : Google Scholar
|
|
4
|
Lo M, Wang YZ and Gout PW: The
x(c)-cystine/glutamate antiporter: a potential target for therapy
of cancer and other diseases. J Cell Physiol. 215:593–602. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ryan BM, Russel MG, Langholz E and
Stockbrugger RW: Aminosalicylates and colorectal cancer in IBD: a
not-so bitter pill to swallow. Am J Gastroenterol. 98:1682–1687.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Narang VS, Pauletti GM, Gout PW, Buckley
DJ and Buckley AR: Suppression of cystine uptake by sulfasalazine
inhibits proliferation of human mammary carcinoma cells. Anticancer
Res. 23:4571–4579. 2003.
|
|
7
|
Gout PW, Simms CR and Robertson MC: In
vitro studies on the lymphoma growth-inhibitory activity of
sulfasalazine. Anticancer Drugs. 14:21–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robe PA, Martin DH, Nguyen-Khac MT, Artesi
M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M and Bours
V: Early termination of ISRCTN45828668, a phase 1/2 prospective,
randomized study of sulfasalazine for the treatment of progressing
malignant gliomas in adults. BMC Cancer. 9:3722009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robe PA, Bentires-Alj M, Bonif M, Rogister
B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP,
et al: In vitro and in vivo activity of the nuclear factor-kappaB
inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res.
10:5595–5603. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Habens F, Srinivasan N, Oakley F, Mann DA,
Ganesan A and Packham G: Novel sulfasalazine analogues with
enhanced NF-κB inhibitory and apoptosis promoting activity.
Apoptosis. 10:481–491. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Müerköster S, Arlt A, Witt M, Gehrz A,
Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR,
et al: Usage of the NF-kappaB inhibitor sulfasalazine as
sensitizing agent in combined chemotherapy of pancreatic cancer.
Int J Cancer. 104:469–476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ogier-Denis E and Codogno P: Autophagy: a
barrier or an adaptive response to cancer. Biochim Biophys Acta.
1603:113–128. 2003.PubMed/NCBI
|
|
13
|
Shintani T and Klionsky DJ: Autophagy in
health and disease: a double-edged sword. Science. 306:990–995.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marino G and Lopez-Otin C: Autophagy:
molecular mechanisms, physiological functions and relevance in
human pathology. Cell Mol Life Sci. 61:1439–1454. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eskelinen EL: Maturation of autophagic
vacuoles in mammalian cells. Autophagy. 1:1–10. 2005. View Article : Google Scholar
|
|
16
|
Djavaheri-Mergny M, Amelotti M, Mathieu J,
Besançon F, Bauvy C, Souquère S, Pierron G and Codogno P: NF-kappaB
activation represses tumor necrosis factor-alpha-induced autophagy.
J Biol Chem. 281:30373–30382. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trocoli A and Djavaheri-Mergny M: The
complex interplay between autophagy and NF-kappaB signaling
pathways in cancer cells. Am J Cancer Res. 1:629–649. 2011.
|
|
18
|
Guan J, Lo M, Dockery P, Mahon S, Karp CM,
Buckley AR, Lam S, Gout PW and Wang YZ: The
xc-cystine/glutamate antiporter as a potential
therapeutic target for small-cell lung cancer: use of
sulfasalazine. Cancer Chemother Pharmacol. 64:463–472. 2009.
View Article : Google Scholar
|
|
19
|
Yu H, Su J, Xu Y, Kang J, Li H, Zhang L,
Yi H, Xiang X, Liu F and Sun L: p62/SQSTM1 involved in cisplatin
resistance in human ovarian cancer cells by clearing ubiquitinated
proteins. Eur J Cancer. 47:1585–1594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
White E, Karp C, Strohecker AM, Guo Y and
Mathew R: Role of autophagy in suppression of inflammation and
cancer. Curr Opin Cell Biol. 22:212–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosenfeldt MT and Ryan KM: The multiple
roles of autophagy in cancer. Carcinogenesis. 32:955–963. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sanz L, Sanchez P, Lallena MJ, Diaz-Meco
MT and Moscat J: The interaction of p62 with RIP links the atypical
PKCs to NF-kappaB activation. EMBO J. 18:3044–3053. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wooten MW, Seibenhener ML, Mamidipudi V,
Diaz-Meco MT, Barker PA and Moscat J: The atypical protein kinase
C-interacting protein p62 is a scaffold for NF-kappaB activation by
nerve growth factor. J Biol Chem. 276:7709–7712. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wooten MW, Geetha T, Seibenhener ML, Babu
JR, Diaz-Meco MT and Moscat J: The p62 scaffold regulates nerve
growth factor-induced NF-kappaB activation by influencing TRAF6
polyubiquitination. J Biol Chem. 280:35625–35629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moscat J, Diaz-Meco MT and Wooten MW:
Signal integration and diversification through the p62 scaffold
protein. Trends Biochem Sci. 32:95–100. 2007. View Article : Google Scholar
|
|
26
|
Moscat J, Diaz-Meco MT, Albert A and
Campuzano S: Cell signaling and function organized by PB1 domain
interactions. Mol Cell. 23:631–640. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duran A, Linares JF, Galvez AS,
Wikenheiser K, Flores JM, Diaz-Meco MT and Moscat J: The signaling
adaptor p62 is an important NF-kappaB mediator in tumorigenesis.
Cancer Cell. 13:343–354. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rolland P, Madjd Z, Durrant L, Ellis IO,
Layfield R and Spendlove I: The ubiquitin-binding protein p62 is
expressed in breast cancers showing features of aggressive disease.
Endocr Relat Cancer. 14:73–80. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su J, Xu Y, Zhou L, Yu HM, Kang JS, Liu N,
Quan CS and Sun LK: Suppression of chloride channel 3 expression
facilitates sensitivity of human glioma U251 cells to cisplatin
through concomitant inhibition of Akt and autophagy. Anat Rec
(Hoboken). 296:595–603. 2013. View
Article : Google Scholar
|
|
30
|
Liu N, Xu Y, Sun JT, Su J, Xiang XY, Yi
HW, Zhang ZC and Sun LK: The BH3 mimetic S1 induces endoplasmic
reticulum stress-associated apoptosis in cisplatin-resistant human
ovarian cancer cells although it activates autophagy. Oncol Rep.
30:2677–2684. 2013.PubMed/NCBI
|
|
31
|
Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge
C, Liang L, Jia D, Chen T, Yao M, et al: Disruption of xCT inhibits
cell growth via the ROS/autophagy pathway in hepatocellular
carcinoma. Cancer Lett. 312:55–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moscat J and Diaz-Meco MT: p62 at the
crossroads of autophagy, apoptosis and cancer. Cell. 137:1001–1004.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zanotto-Filho A, Braganhol E, Schröder R,
De Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM and
Moreira JC: NFkappaB inhibitors induce cell death in glioblastomas.
Biochem Pharmacol. 81:412–424. 2011. View Article : Google Scholar
|
|
35
|
Kesanakurti D, Chetty C, Rajasekhar
Maddirela D, Gujrati M and Rao JS: Essential role of cooperative
NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements
in the regulation of radiation-induced invasion and migration in
glioma. Oncogene. 32:5144–5155. 2013. View Article : Google Scholar
|
|
36
|
Chung WJ, Lyons SA, Nelson GM, Hamza H,
Gladson CL, Gillespie GY and Sontheimer H: Inhibition of cystine
uptake disrupts the growth of primary brain tumors. J Neurosci.
25:7101–7110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moriuchi S, Glorioso JC, Maruno M, Izumoto
S, Wolfe D, Huang S, Cohen JB and Yoshimine T: Combination gene
therapy for glioblastoma involving herpes simplex virus
vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine
kinase. Cancer Gene Ther. 12:487–496. 2005.PubMed/NCBI
|
|
38
|
Martin P, Diaz-Meco MT and Moscat J: The
signaling adapter p62 is an important mediator of T helper 2 cell
function and allergic airway inflammation. EMBO J. 25:3524–3533.
2006. View Article : Google Scholar : PubMed/NCBI
|
